



- (51) **International Patent Classification:**
A61K 31/505 (2006.01) *C07D 239/28* (2006.01)
- (21) **International Application Number:**
PCT/US2014/052389
- (22) **International Filing Date:**
22 August 2014 (22.08.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/869,174 23 August 2013 (23.08.2013) US
- (71) **Applicant:** **AFFERENT PHARMACEUTICALS INC.**
[US/US]; 2755 Campus Drive, Suite 100, San Mateo, California 94403 (US).
- (72) **Inventors:** **FORD, Anthony P.**; 3087 Ross Road, Palo Alto, California 94303 (US). **MCCARTHY, Bruce G.**; 251 Bonview Street, San Francisco, California 94110 (US).
- (74) **Agents:** **ERLACHER, Heidi A.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, N.W., Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) **Title:** DIAMINOPYRIMIDINE P2X3 AND P2X 2/3 RECEPTOR MODULATORS FOR TREATMENT OF ACUTE, SUB-ACUTE OR CHRONIC COUGH




FIGURE 1

(57) **Abstract:** This invention pertains to diaminopyrimidine compounds having activity as antagonists of P2X purinergic receptors, and to methods for treatment of diseases associated with P2X receptors comprising administering an effective amount of a diaminopyrimidine compound. More particularly, methods are provided for using P2X3 and/or P2X2/3 antagonists in the treatment of cough, chronic cough and urge to cough in respiratory conditions and disorders.

WO 2015/027212 A1



Published:

— *with international search report (Art. 21(3))*